期刊文献+

白细胞介素-6对子宫颈癌细胞株C-33A增殖影响的研究 被引量:2

Research on the effects of interleukin-6 on proliferation of cervical cancer cell C-33A
原文传递
导出
摘要 目的探讨白细胞介素-6(interleukin-6,IL-6)在子宫颈癌中的作用。方法将培养后的子宫颈癌细胞C-33A分为IL-6组和对照组,IL-6组使用IL-6(50 ng/m L)刺激,对照组不加入IL-6,利用MTT比色法检测细胞增殖,划痕实验检测细胞迁移,实时荧光定量聚合酶链反应技术检测上皮钙黏着蛋白(epithelial-cadherin,ECad)、神经钙黏着蛋白(neural-cadherin,N-Cad)、波形蛋白(vimentin)、转录因子Snail1(transcription factorssnail1,TFs-SNAIL1)在m RNA水平上的表达,蛋白质印迹法检测E-Cad、N-Cad、Vimentin、TFs-SNAIL1蛋白水平的表达。结果与对照组比较,IL-6组子宫颈癌细胞株C-33A增殖活性更高(12 h:0.388±0.025 vs.0.597±0.057;24 h:0.547±0.021 vs.0.798±0.036;48 h:0.745±0.056 vs.1.296±0.122;72 h:1.074±0.053 vs.1.805±0.113;P<0.05),迁移能力更强(12 h:1.057±0.029 vs.1.200±0.045;24 h:1.189±0.036 vs.1.428±0.181;48 h:1.273±0.059 vs.1.569±0.143;72 h:1.409±0.047 vs.1.623±0.170;P<0.05),E-Cad m RNA及蛋白的表达更低(1.012±0.098 vs.0.483±0.171,P<0.01;1.032±0.015 vs.0.395±0.119,P<0.01),N-Cad m RNA及蛋白表达更高(1.054±0.106 vs.1.465±0.230,P<0.01;1.040±0.043 vs.1.605±0.128,P<0.01),vimentin m RNA及蛋白表达更高(1.050±0.083 vs.1.340±0.099,P<0.05;1.043±0.062 vs.1.430±0.077,P<0.05),TFs-SNAIL1 m RNA及蛋白表达更高(1.058±0.176 vs.1.510±0.229,P<0.01;1.022±0.015 vs.1.470±0.139,P<0.01)。结论 IL-6可能促进子宫颈癌细胞株C-33A的增殖、迁移和上皮-间质转化。 Objective To explore the role of interleukin-6 (IL-6) in cervical cancer cell C-33A. Methods The cervical cancer cells C-33A were divided into the IL-6 group and the control group after culture. The IL-6 group were treated with 50 ng/mL of recombinant IL-6 protein, and the control group were without IL-6. Then cell viability and cell migration were detected by MTT assay and wound-healing assay, respectively. The mRNA and protein expressions of epithelial-cadherin (E-Cad), neural-cadherin (N-Cad), vimentin and transcription factors-snaill (TFs-SNAIL1) were analyzed by real time quantitative polymerase chain reaction and Western blotting, respectively. Results Compared with the control group, in the IL-6 group the proliferation of cervical cancer cells C-33A was promoted (12 h: 0.388±0.025 vs. 0.597±0.057; 24 h: 0.547±0.021 vs. 0.798±0.036; 48 h: 0.745±0.056 vs. 1.296±0.122; 72 h: 1.074±0.053 vs. 1.805±0.113; P〈0.05), and the relative migration ability of cervical cancer cell was promoted (12 h: 1.057±0.029 vs. 1.200±0.045; 24 h: 1.189±0.036 vs. 1.428±0.181; 48 h: 1.273±0.059 vs. 1.569±0.143; 72 h: 1.409±0.047 vs. 1.623±0.170; P〈0.05); meanwhile, compared with the control group, in the IL-6 group, the expression of E-Cad mRNA (1.012±0.098 vs. 0.483±0.171, P〈0.01) and E-Cad protein (1.032±0.015 vs. 0.395±0.119; P〈0.01) decreased, the expression of N-Cad mRNA (1.054±0.106 vs. 1.465±0.230, P〈0.01) and N-Cad protein (1.040±0.043 vs. 1.605±0.128, P〈0.01) increased, the expression ofvimentin mRNA (1.050±0.083 vs. 1.340±0.099, P〈0.05) and vimentin protein (1.043±0.062 vs. 1.430±0.077, P〈0.05) increased, and the expression ofTFs-SNAIL1 mRNA (1.058±0.176 vs. 1.510±0.229, P〈0.01) and Fs-SNAILI protein (1.022±0.015 vs. 1.470±0.139, P〈0.01) increased. Conclusion IL-6 may promote the proliferation, migration, and epithelial-mesenchymal transition of cervical cancer cell C-33A.
作者 唐林 王琪琳 王平 TANG Lin;WANG Qilin;WANG Ping(Emergency Department of Obsterics and Gynecology, West China Second Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education,Chengdu, Sichuan 610041, P. R. China)
出处 《华西医学》 CAS 2018年第4期423-426,共4页 West China Medical Journal
基金 四川省卫生和计划生育委员会科研课题(16PJ232)
关键词 子宫颈癌 白细胞介素-6 细胞上皮-间质转换 Cervical cancer Interleukin-6 Epithelial-mesenchymal transition
  • 相关文献

参考文献3

二级参考文献14

  • 1Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth Factor (VEGF) in human breast cancer: Correlation with disease-free survival [J]. IntJ Cancer, 1997, 74(4):455~458.
  • 2Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia [J].J Natl Cancer Inst, 1995, 87(16):1237 ~ 1245.
  • 3KodamaJ, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer [J]. Eur J Cancer, 1999, 35(3):485~489.
  • 4Tokumo K, Kodama J, Seki N, et al. Different angiogenic pathways in human cervical cancers [J]. Gynecol Oncol, 1998, 68(1):38 ~44.
  • 5Lin HH, Cheng WF, Chan KW, et al. Risk factors for recurrence inpatients with stage IB, ⅡA, and ⅡB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation [J]. Obstet Gynecol, 1996, 88(2):274~279.
  • 6Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells [J]. Cancer Res, 1997, 57(18) :3924 ~3928.
  • 7Castrilli G, Tatone D, Diodoro MG, et al. Interluekin 1-alpha and Interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells [J]. Br J Cancer,1997, 75(6):855~859.
  • 8Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 solube receptor regulate proliferation of normal,human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro [J]. AmJ Pathol,1995, 146(4):944~952.
  • 9Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 in Cervical-Cancer: The Relationship with VEGF [J]. Gynecol Oncol, 2001,82 (1) :49~ 56.
  • 10Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 Induces the Expression of Vascular Endothelial Growth Factor [J]. J Biol Chem, 1996, 271(2):736~741.

共引文献27

同被引文献11

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部